Seattle Genetics and Agensys (now owned by Astellas) will work on their second ADC together under the terms of their existing 2007 agreement. The new project will develop ASG-22ME directed to the Neclin-4 antigen found on bladder, breast, lung and pancreatic tumors.
With this deal, Seattle Genetics says it now has 15 ADC projects underway between its own pipeline and through external collaborations. Agensys says the deal confirms its commitment to ADCs and building its cancer portfolio. Seattle Genetics expects its first ADC, brentuximab vedotin (SGN-35), to be approved sometime this year by the FDA. See PBR.
Posted by Bruce Lehr June 9th 2011.
Comments